Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma
- 1.2k Downloads
Program death 1 (PD-1) and its ligand (PD-L1) have been identified as potential therapeutic targets for solid and hematologic malignancies. The current study aimed to assess PD-L1 expression in intrahepatic cholangiocarcinoma (ICC) and relate clinical outcomes to its expression.
Formalin-fixed, paraffin-embedded tumor specimens were obtained for patients undergoing surgery at Johns Hopkins Hospital between 1991 and 2011. Immunohistochemistry was used to assess PD-L1 expression in tumor-associated macrophages (TAMs) and within the tumor front (TF).
Of 54 tumor samples analyzed, 34 stained positive for PD-L1 expression on TAMs (TAMs+), and 39 stained positive for PD-L1 expression on cells within the tumor front (TF+). The TF+ patients were less likely to present with metastatic lymph nodes (N1 patients: 26.7 vs 7.7 %; p = 0.011), whereas all tumors with intrahepatic metastasis failed to demonstrate staining for PD-L1 around the tumor front (p = 0.020). Patients with tumors shown to be TAMs+ were less likely to present with multiple lesions (35.0 vs 8.8 %; p = 0.017). Patients with tumors exhibiting PD-L1 expression around the tumor front demonstrated a worse overall survival than TF patients (p = 0.008). Multivariable analysis showed that patients with tumors staining for PD-L1 in the tumor front had a 59.5 % reduced survival (TF− vs TF+: time ratio, 0.405; 95 % confidence interval, 0.215–0.761; p = 0.005).
Expression of PD-L1 was noted among a majority of patients, and PD-L1 expression within the tumor front was associated with a 60 % decreased survival. Future clinical trials are necessary to assess the safety and efficacy of anti-PD-L1 therapies among patients with ICC.
KeywordsOverall Survival Tumor Microenvironment Cholangiocarcinoma Intrahepatic Cholangiocarcinoma Akaike Information Criterion
Conflict of interest
Dr. Robert A. Anders receives research funding from Bristol-Myers Squibb and Five Prime Diagnostics. The remaining authors have no conflicts of interests.
- 17.Leyva-Illades D, McMillin M, Quinn M, et al. Cholangiocarcinoma pathogenesis: role of the tumor microenvironment. Transl Gastrointest Cancer. 2012;1:71–80. Retrieved 7 Sep 2015 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3448449&tool=pmcentrez&rendertype=abstract.
- 20.Ramanathan S, Jagannathan N. Tumor-associated macrophage: a review on the phenotypes, traits, and functions. Iran J Cancer Prev. 2014;7:1–8. Retrieved 2 Sep 2015 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4142950&tool=pmcentrez&rendertype=abstract.